Ectopic pregnancy is one of the common causes of intra-abdominal bleeding, which is a gynecological emergency that, undiagnosed in time, can lead to death. About 95-96% of the ectopic pregnancies are implanted in different segments of the uterus. The purpose of the present paper is to evaluate the criteria for administration of methotrexate and to determine its effectiveness in the medicinal treatment of ectopic tubal pregnancy. It has been found that medical treatment w methotrexate is indicated in patients with uncomplicated (non-rupture), hemodynamically stable extrauterine pregnancy, with minimal symptomatology and no intraperitoneal fluid. We used a large volume of bibliographic resources and conducted a retrospective study on the use of methotrexate in ectopic tubal pregnancy. In the retrospective study, 841 observation sheets of patients with tubal ectopic pregnancy admitted to the aseptic Gynecology section of the SCM IMSP No.1 were studied, between 2012 and 2018. The statistical collectivity under analysis is made up of 55 clinical cases undergoing drug treatment with methotrexate, constituting the baseline group, and 55 clinical cases undergoing surgical treatment (tubectomy) were selected, which included the control group. According to data from randomized clinical trials, methotrexate treatment is applied depending on the initial serum β-hCG level. The weighted average of the initial level of β-hGC I in the control group constituted 1536.4±128.3 IU/L, and in the control group - 2209.1±185.4 IU/L with a statistically significant difference. All patients in the control group receive intramuscular methotrexate, of which 52 patients received a single dose at 50 mg/m², and 3 pregnant women received multiple doses. In 14 (25.5%) cases of observation there were adverse effects, which were manifested by digestive disorders 3 (5.5% cases and ineffective treatment - 11 (20.0%) cases. We found that of the 11 patients whose treatment was shown to be ineffective 8 (72.7%) patients had ectopic pregnancy in the anamnesis, 5 (45.5%) women had aggravated obstetricgynecological anamnesis, 4 (36.4%) patients had previous abortions and 3 (27.3%) pregnant women suffered fr extragenital pathologies. The success of methotrexate drug treatment in tubal ectopic pregnancy avoids the risk of surgery and at the same time does not affect fertility. The 50mg/m² single dose treatment regimen is most appropriate considering the minimal side effects.